PARTICULARS TO APPEAR ON THE OUTER PACKAGE
{Plastic box containing vials of lyophilisate and solvent}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Canigen KC nasal drops, lyophilisate and solvent for suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Each 0.4 ml dose of reconstituted vaccines contains:
Bordetella bronchiseptica, strain B-C2, live: $10^{8.0}$ – $10^{9.7}$cfu
Canine parainfluenza virus, strain Cornell, live: $10^{3.0}$ – $10^{5.8}$ $TCID_{50}$

3. PACKAGE SIZE

1 x 1 dose vaccine + 1 x solvent
5 x 1 dose vaccine + 5 x solvent
10 x 1 dose vaccine + 10 x solvent
25 x 1 dose vaccine + 25 x solvent
50 x 1 dose vaccine + 50 x solvent
1x 5 doses vaccine + 1 x 5 doses solvent
5 x 5 doses vaccine + 5 x 5 doses solvent
10 x 5 doses vaccine + 10 x 5 doses solvent
25 x 5 doses vaccine + 25 x 5 doses solvent
50 x 5 doses vaccine + 50 x 5 doses solvent
1x 10 doses vaccine + 1 x 10 doses diluent
5 x 10 doses vaccine + 5 x 10 dose diluent
10 x 10 doses vaccine + 10 x 10 doses diluent
25 x 10 doses vaccine + 25 x 10 doses diluent
50 x 10 doses vaccine + 50 x 10 doses diluent

4. TARGET SPECIES

Dogs

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Nasal use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use within 1 hour.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

14. MARKETING AUTHORISATION NUMBER

Vm 06376/4115

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
{Cardboard box containing vials of lyophilisate and solvent}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Canigen KC nasal drops, lyophilisate and solvent for suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Each 0.4 ml dose of reconstituted vaccine contains:
Bordetella bronchiseptica, strain B-C2, live: $10^{8.0} – 10^{9.7}$cfu
Canine parainfluenza virus, strain Cornell, live: $10^{3.0} – 10^{5.8}$ $TCID_{50}$

3. PACKAGE SIZE

1 x 1 dose vaccine + 1 x solvent
5 x 1 dose vaccine + 5 x solvent
10 x 1 dose vaccine + 10 x solvent
25 x 1 dose vaccine + 25 x solvent
50 x 1 dose vaccine + 50 x solvent
1x 5 doses vaccine + 1 x 5 doses solvent
5 x 5 doses vaccine + 5 x 5 doses solvent
10 x 5 doses vaccine + 10 x 5 doses solvent
25 x 5 doses vaccine + 25 x 5 doses solvent
50 x 5 doses vaccine + 50 x 5 doses solvent
1x 10 doses vaccine + 1 x 10 doses diluent
5 x 10 doses vaccine + 5 x 10 doses diluent
10 x 10 doses vaccine + 10 x 10 doses diluent
25 x 10 doses vaccine + 25 x 10 doses diluent
50 x 10 doses vaccine + 50 x 10 doses diluent

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Nasal use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use within 1 hour.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

Allow the solvent to reach room temperature.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

14. MARKETING AUTHORISATION NUMBER

Vm 06376/4115

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {Vaccine vial label}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Canigen KC

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

B. bronchiseptica: ≥ $10^{8.0}$ cfu
CPi: ≥ $10^{3.0}$ $TCID_{50}$

1 dose
5 doses
10 doses

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use within 1 hour.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {Solvent vial label}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Canigen KC
Sterile solvent for the reconstitution of Canigen KC.

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 dose
5 doses
10 doses

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Canigen KC nasal drops, lyophilisate and solvent for suspension for dogs

2. Composition

Each 0.4 ml dose of reconstituted vaccine contains:

Bordetella bronchiseptica, strain B-C2, live:	$10^{8.0}$ – $10^{9.7}$cfu
Canine parainfluenza virus, strain Cornell, live:	$10^{3.0}$ – $10^{5.8}$ $TCID_{50}$

[1]colony forming units
[2]Tissue Culture Infective Dose 50%

Lyophilisate: off-white or cream-coloured pellet.
Solvent: clear colourless solution.

3. Target species

Dogs.

4. Indications for use

Active immunisation of dogs against *Bordetella bronchiseptica* and canine parainfluenza virus for periods of increased risk to reduce clinical signs induced by *B. bronchiseptica* and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus.

Onset of immunity: *Bordetella bronchiseptica*: 72 hours after vaccination;
Canine parainfluenza virus: 3 weeks after vaccination.

Duration of immunity: 1 year

5. Contraindications

None known.

6. Special warnings

Special warnings:
Vaccinate healthy animals only.

Special precautions for safe use in the target species:
Vaccinated dogs may excrete the *Bordetella bronchiseptica* vaccine strain up to 6 weeks and the canine parainfluenza vaccine strain up to a few days following vaccination. During this time, the contact of immunosuppressed and unvaccinated dogs with vaccinated dogs should be avoided.
Immunosuppressive medication may impair the development of active immunity and may increase the chance of adverse effects caused by the live vaccine strains.
Cats, pigs and unvaccinated dogs may react to the vaccine strains with mild and transient respiratory signs. Other animals, like rabbits and small rodents have not been tested.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Immunocompromised persons are advised to avoid contact with the vaccine and vaccinated dogs up to 6 weeks after vaccination.
Disinfect hands and equipment after use.

Pregnancy:
Can be used during pregnancy.

Interaction with other medicinal products and other forms of interaction:
Do not administer in conjunction with other intranasal treatments or during antibiotic treatment.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed, with the live vaccines in the Canigen range against canine distemper, canine contagious hepatitis caused by canine adenovirus type 1, canine parvovirus disease and respiratory disease caused by canine adenovirus type 2, where authorised, and inactivated vaccines in the Canigen range against canine leptospirosis caused by all or some of the following serovars: *L. interrogans* serogroup Canicola serovar Canicola, *L. interrogans* serogroup Icterohaemorrhagiae serovar Copenhageni, *L. interrogans* serogroup Australis serovar Bratislava, and *L. kirschneri* serogroup Grippotyphosa serovar Bananal/Liangguang. In very rare cases a transient acute hypersensitivity reaction may occur when this product is used with other vaccines.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
In case antibiotics are administered within one week after vaccination, the vaccination should be repeated after the antibiotic treatment is finished.

Overdose:
Particularly in very young puppies, signs of upper respiratory tract disease have been observed after a 10-fold overdose of the vaccine, including ocular and nasal discharges, pharyngitis, sneezing and coughing. The signs started the day after vaccination and have been seen for up to 4 weeks after vaccination.

Major incompatibilities:
Do not mix with any other veterinary medicinal product, except the solvent recommended for use with the veterinary medicinal product.

7. Adverse events

Dogs:

Very common (>1 animal / 10 animals treated):	Nasal discharge[1]. Ocular discharge[1].
Common (1 to 10 animals / 100 animals reacted):	Sneezing[1], cough[1].
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Wheezing[1]. Lethargy. Vomiting. Hypersensitivity reaction, anaphylactic-type (allergic) reaction [2]. Immune mediated haemolytic anaemia (low amounts of red blood cells), immune mediated thrombocytopenia (decreased platelet count), immune mediated polyarthritis (inflammation of the joints).

[1] Particularly observed in very young susceptible puppies. Signs are generally mild and transient, but in occasional cases may persist for up to four weeks. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
[2] Such reaction may evolve to a more severe condition, which may be life-threatening. If such reaction occurs appropriate treatment should be administered without delay.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Nasal use.
Administer one dose of 0.4 ml per animal.
Reconstitute 1 vial of vaccine with 1 vial of solvent.

Vaccination scheme:
Dogs should be at least 3 weeks of age. When this vaccine is concurrently administered (i.e. not mixed) with another vaccine in the Canigen range as indicated

in section Special warnings, dogs should not be younger than the minimum age recommended for the other Canigen vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of anticipated risk, e.g. temporary kennelling in order to get protection for both vaccine agents. In order to get protection for *Bordetella bronchiseptica* unvaccinated dogs should receive one dose at least 72 hours prior to the period of anticipated risk (see also section ‘Special warnings’).

Revaccinate annually.

9. Advice on correct administration

Allow the sterile solvent provided to reach room temperature (15 °C – 25 °C).
Aseptically reconstitute the lyophilisate with the solvent. Shake the vial well after addition of the solvent. Withdraw the vaccine into the syringe, remove the needle and administer 0.4 ml directly from the tip of the syringe into one nostril.
The reconstituted vaccine is an off-white or yellowish coloured suspension.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: 1 hour.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription

14. Marketing authorisation numbers and pack sizes

Vm 06376/4115

Pack sizes
Cardboard or plastic box with 10 or 50 glass vials containing equal amounts (5 + 5 or 25 + 25) of 1, 5 or 10 doses of the vaccine and 0.6, 2.4, 4.6 ml of the solvent.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Contact details to report suspected adverse reactions:

UK(GB)	**UK(NI)**
MSD Animal Health UK Ltd.	Intervet Ireland Ltd.
Tel.: +44(0)1908 685685	Tel.: +353(0)1 297 0220

Local representatives:
MSD Animal Health UK Limited
Walton Manor, Walton
Milton Keynes
MK7 7AJ, United Kingdom

Distributor:
Virbac Ltd.
Woolpit Business Park
Windmill Avenue
Woolpit
Bury St. Edmunds
Suffolk, IP30 9UP

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall
Approved 24 July 2026